Regulatory Pressure Mounts for Telehealth Firm Hims & Hers
Published on 09/24/2025 at 16:36 | Redaktion boerse-global.de
The telehealth company Hims & Hers finds itself navigating a significant regulatory challenge following action by the U.S. Food and Drug Administration (FDA). This development casts a shadow over the firm’s otherwise impressive growth trajectory, raising questions about the impact on its future performance.
Despite the emerging regulatory concerns, the company’s operational results for the second quarter of 2025 were exceptionally strong. The financial and subscriber metrics underscore its rapid expansion:
- Revenue reached $544.8 million, representing a substantial 73% year-over-year increase.
- The subscriber base grew to over 2.4 million, a 31% jump compared to the previous year.
- Net income was reported at $42.5 million.
- Management has reaffirmed its full-year... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
